TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
Expedia Group stock rose sharply after announcing an expanded, exclusive partnership with Affirm, making the fintech firm the sole 'Buy Now, Pay Later' provider across its major U.S. travel platforms.
Terex Corporation shares gained over 4% following the finalization of its merger with REV Group, creating a diversified specialty equipment giant. The deal is projected to yield $75 million in annual synergies by 2028.
While the S&P 500 remains a core holding for many, actively managed and thematic ETFs offer a path to potentially superior returns. We analyze three Fidelity funds with distinct strategies—from U.S. tech dominance to international dividend income—that have historically beaten the market.
In a strategic reshuffle following the exit of its product chief, Netflix has merged its product and technology divisions under veteran executive Elizabeth Stone, signaling a tighter integration of engineering and user experience.
Former President Donald Trump's recent comments advocating for higher housing prices have ignited debate, as experts warn such a stance could deepen the affordability crisis for younger generations and renters.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
London's blue-chip index surged to a historic high as investors rotated into defensive sectors, shrugging off a brutal sell-off in precious metals and oil triggered by geopolitical shifts and regulatory moves.
A broad sell-off in risk assets, from equities to precious metals, has triggered over $2.5 billion in Bitcoin liquidations. Analysts point to shifting Federal Reserve expectations and AI trade anxieties as key drivers behind the latest crypto market tremor.
CNBC's Jim Cramer lauds Salesforce's operational strength, yet the stock, alongside peer ServiceNow, faces persistent 'multiple compression' as Wall Street reevaluates growth expectations for mature software leaders.
CNBC's Jim Cramer offered a measured take on data security firm Rubrik (NYSE:RBRK), suggesting investors wait for market volatility to settle before considering a position, while highlighting the crowded nature of the sector.
CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.
CNBC's Jim Cramer expressed reservations about aviation services provider AAR Corp., highlighting its 15% gross yield as a potential red flag for investors during a recent market analysis segment.
CNBC's Jim Cramer highlighted International Business Machines Corp. (IBM) as a standout AI investment with a relatively modest valuation, following a robust quarterly report that sent shares soaring.
CNBC's Jim Cramer positions Alphabet as the potential 'only winner in AI,' suggesting its upcoming earnings may show it generating more revenue from AI than rival Meta Platforms.
CNBC's Jim Cramer concedes he misjudged the explosive demand for Apple's iPhone 17, which powered the tech giant to a staggering earnings beat that caught Wall Street off guard.
